← Leaderboards
Dennis E Kyle
U.S. Walter Reed Army Inst Of Research
$9,984,601
Attributed
$20,807,972
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$20,807,972 · 13
By mechanism
R01$16,282,357 · 5
R21$2,510,146 · 6
T32$1,864,469 · 1
R03$151,000 · 1
Top collaborators
- Roman Manetsch15 shared
- Silvia N Moreno6 shared
- R Kiplin Guy5 shared
- Spencer A Knapp5 shared
- David Armand Fidock4 shared
- BenoãT Witkowski3 shared
- Bill J Baker2 shared
- Jeremy Nicholas Burrows2 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsInfectionIn VitroResistanceMalariaPlasmodium FalciparumSeriesBaseDrug ResistanceErythrocytesCombined Modality TherapyPropertyIn VivoParasitesLeadTransmission ProcessAntimalarialsDoseEvaluationCulicidaeDrug DevelopmentDrug DiscoveryCountryArtemisinins
Grant awards (44)
Lead optimization and target identification of drugs targeting hypnozoites$649,072
R01 · FY2024 · AI · contact PI
Training in Tropical and Emerging Global Diseases$431,221
T32 · FY2024 · AI
Elucidating mechanisms for artemisinin-induced dormancy in Plasmodium falciparum$188,750
R21 · FY2024 · AI · contact PI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$701,000
R01 · FY2023 · AI
Lead optimization and target identification of drugs targeting hypnozoites$656,698
R01 · FY2023 · AI · contact PI
Training in Tropical and Emerging Global Diseases$365,956
T32 · FY2023 · AI
Elucidating mechanisms for artemisinin-induced dormancy in Plasmodium falciparum$226,500
R21 · FY2023 · AI · contact PI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$708,550
R01 · FY2022 · AI
Lead optimization and target identification of drugs targeting hypnozoites$661,635
R01 · FY2022 · AI · contact PI
Training in Tropical and Emerging Global Diseases$359,472
T32 · FY2022 · AI
Training in Tropical and Emerging Global Diseases - Supplement$32,000
T32 · FY2022 · AI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$704,775
R01 · FY2021 · AI
Lead optimization and target identification of drugs targeting hypnozoites$680,269
R01 · FY2021 · AI · contact PI
Training in Tropical and Emerging Global Diseases$359,887
T32 · FY2021 · AI
Repurposing drugs for treatment of primary amoebic meningoencephalitis$75,500
R03 · FY2021 · AI · contact PI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$713,835
R01 · FY2020 · AI
Lead optimization and target identification of drugs targeting hypnozoites$702,238
R01 · FY2020 · AI · contact PI
Training in Tropical and Emerging Global Diseases$315,933
T32 · FY2020 · AI
Combining Liver Stage Culture System with Backcross Genetics to Discover Antimalarial Drug Resistance Loci$188,750
R21 · FY2020 · AI · contact PI
Repurposing drugs for treatment of primary amoebic meningoencephalitis$75,500
R03 · FY2020 · AI · contact PI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$725,226
R01 · FY2019 · AI
Combining Liver Stage Culture System with Backcross Genetics to Discover Antimalarial Drug Resistance Loci$226,000
R21 · FY2019 · AI · contact PI
Lead Optimization of Bis-benzimidazole Analogs for Pathogenic Free-living Amoebae$123,103
R21 · FY2016 · AI · contact PI
Lead Optimization of Bis-benzimidazole Analogs for Pathogenic Free-living Amoebae$96,140
R21 · FY2016 · AI · contact PI
Validation of New Antimalarial Leads$1,190,932
R01 · FY2015 · AI
Lead Optimization of Bis-benzimidazole Analogs for Pathogenic Free-living Amoebae$206,081
R21 · FY2015 · AI · contact PI
Extreme Resistance to Mitochondrial Inhibitors in Plasmodium falciparum$178,364
R21 · FY2015 · AI · contact PI
Validation of New Antimalarial Leads$1,190,932
R01 · FY2014 · AI
Natural Product Treatments for Leishmaniasis$224,250
R21 · FY2014 · AI
Extreme Resistance to Mitochondrial Inhibitors in Plasmodium falciparum$212,547
R21 · FY2014 · AI · contact PI
New Therapies for Pathogenic Free-Living Amoebae$197,689
R21 · FY2014 · AI · contact PI
Validation of New Antimalarial Leads$1,119,476
R01 · FY2013 · AI
New Therapies for Pathogenic Free-Living Amoebae$266,309
R21 · FY2013 · AI · contact PI
Natural Product Treatments for Leishmaniasis$175,663
R21 · FY2013 · AI
Validation of New Antimalarial Leads$1,190,932
R01 · FY2012 · AI
Validation of New Antimalarial Leads$1,238,884
R01 · FY2011 · AI
Pharmacologic Approaches to Combating Resistance to Antimalarial Combinations$557,200
R01 · FY2011 · AI
Pharmacologic Approaches to Combating Resistance to Antimalarial Combinations$581,479
R01 · FY2010 · AI
Pharmacologic Approaches to Combating Resistance to Antimalarial Combinations$589,796
R01 · FY2009 · AI
Pharmacologic Approaches to Combating Resistance to Antimalarial Combinations$579,356
R01 · FY2008 · AI
Artemisinin-induced Dormancy & Malaria Treatment Failure$316,680
R01 · FY2008 · AI · contact PI
Artemisinin-induced Dormancy & Malaria Treatment Failure$266,286
R01 · FY2007 · AI · contact PI
Artemisinin-induced Dormancy & Malaria Treatment Failure$271,795
R01 · FY2006 · AI · contact PI
Artemisinin-induced Dormancy &Malaria Treatment Failure$285,311
R01 · FY2005 · AI